Loading
A phase 1/2 trial of Clifutinib in acute myeloid leukaemia, run by Sunshine Lake Pharma Co., Ltd., now recruiting.
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML is a phase 1/2 interventional study registered as NCT05133882 by Sunshine Lake Pharma Co., Ltd., with 133 participants planned, started 2022-10-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: Clifutinib Besylate.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
Shares Clifutinib, Sunshine Lake Pharma (HEC), Acute myeloid leukaemia.
Shares Sunshine Lake Pharma (HEC) and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/